Swiss National Bank Arcus Biosciences, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Swiss National Bank holds 98,296 shares of RCUS stock, worth $1.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

98,296

Previous 98,296 -0.0%

Holding current value

$1.55 Million

Previous $1.5 Million 0.33%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$14.59 - $18.48 $42,311 - $53,592	2,900 Added 3.04%	98,296 $1.5 Million
Q4 2023 Feb 06, 2024	SELL	$13.43 - $19.63 $120,870 - $176,670	-9,000 Reduced 8.62%	95,396 $1.82 Million
Q3 2023 Nov 08, 2023	BUY	$17.62 - $23.54 $160,342 - $214,214	9,100 Added 9.55%	104,396 $1.87 Million
Q2 2023 Aug 09, 2023	BUY	$16.97 - $22.03 $27,152 - $35,248	1,600 Added 1.71%	95,296 $1.94 Million
Q1 2023 May 10, 2023	SELL	$15.96 - $23.15 $172,368 - $250,019	-10,800 Reduced 10.34%	93,696 $1.71 Million
Q4 2022 Feb 08, 2023	BUY	$19.7 - $35.71 $49,250 - $89,275	2,500 Added 2.45%	104,496 $2.16 Million
Q3 2022 Nov 09, 2022	BUY	$23.23 - $30.07 $34,845 - $45,105	1,500 Added 1.49%	101,996 $2.67 Million
Q2 2022 Aug 09, 2022	BUY	$17.23 - $37.73 $158,516 - $347,116	9,200 Added 10.08%	100,496 $2.55 Million
Q1 2022 May 09, 2022	BUY	$28.92 - $41.83 $138,816 - $200,784	4,800 Added 5.55%	91,296 $2.88 Million
Q4 2021 Feb 08, 2022	BUY	$31.38 - $48.47 $18,828 - $29,082	600 Added 0.7%	86,496 $3.5 Million
Q2 2021 Aug 06, 2021	SELL	$22.75 - $35.77 $241,150 - $379,162	-10,600 Reduced 10.98%	85,896 $2.36 Million
Q1 2021 May 07, 2021	BUY	$26.16 - $41.39 $28,776 - $45,529	1,100 Added 1.15%	96,496 $2.71 Million
Q4 2020 Feb 05, 2021	BUY	$17.0 - $32.36 $197,200 - $375,376	11,600 Added 13.84%	95,396 $2.48 Million
Q3 2020 Nov 09, 2020	BUY	$17.14 - $25.47 $22,282 - $33,111	1,300 Added 1.58%	83,796 $1.44 Million
Q2 2020 Aug 05, 2020	BUY	$13.97 - $36.56 $530,804 - $1.39 Million	37,996 Added 85.38%	82,496 $2.04 Million
Q1 2020 May 08, 2020	BUY	$8.78 - $19.28 $11,414 - $25,064	1,300 Added 3.01%	44,500 $618,000
Q4 2018 Feb 13, 2019	BUY	$9.74 - $14.5 $420,768 - $626,400	43,200 New	43,200 $465,000

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.7M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.14B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Arcus Biosciences, Inc. Transaction History